By the num­bers: As the pan­dem­ic biotech boom fades, it's be­gin­ning to look a lot like 2019 — or be­fore

This year, with Nas­daq iced over, every­thing is falling be­hind. A quick turn to CDER’s ap­provals for the year re­veals that the group has stamped an OK on on­ly 28 drugs, well be­hind the 42 record­ed by this date in 2021. And with man­u­fac­tur­ing in­spec­tions in Chi­na on hold, as well as the gen­er­al lin­ger­ing fall­out from the pan­dem­ic, there are no signs of a come­back in the last two months of the year.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN